Abstract
Background: Many parameters are included to determine the risk stratification of Acute Lymphoblastic Leukemia (ALL), Philadelphia Chromosome (Ph)/BCR-ABL–positive (ALL) is the largest genetically defined subtype in adult ALL with poor outcome. Here, we detected IL-2Rα (CD25) in patients with ALL and explored its diagnostic and prognostic value.
Patients and methods : Thirty ALL patients were recruited in Egypt , newly diagnosed with ages above 18 years old, after informed consent they invited to perform CD25 marker using Coulter EPICSXL, PCR for BCR – ABL fusion gene and Fluorescence in Situ Hybridization (FISH) were also performed along with CBC, LDH, Uric acid, CT scan allover and testicular ultrasonography.
Results: (70%) of patients were males while (30%) were females with no statistically significant difference as correlated with CD25, 13 (43. 33%) patients had positive CD25 , recurrent infections had occurred in 8 patients (26. 67%) with no significant correlation with CD25 (P = 0. 361), 16(53. 33%) patients suffered from fever, while 5 (16. 67%) experienced bleeding with no significant correlation among them with CD 25 (P> 0.05 in both). FISH cytology and PCR were positive in 11 (36.67%) patients. There was highly statistically significant correlation among CD25 and FISH and PCR for BCR-ABL, LDH, total leucocytic count with (P value <0.001). We showed that CD25 measurements compare favorably with other ALL prognostic criteria.
Conclusion: (CD25) expression was corresponding to Philadelphia chromosome. IL-2R α (CD25) is proved to be a valuable marker for monitoring ALL patients, an important parameter for prognosis and follow-up of ALL patients
Citation
Asfour IA, El Din GMKS, Said RMM and Juadam EM. Evaluation of CD 25 (IL2 Receptor Alpha) Expression in Adult Acute Lymphoblastic Leukemia Patients. SM J Hematol Oncol. 2017; 2(1): 1005s